Hyperfixed

Hyperfixed & Radiotopia
Hyperfixed

Maybe it’s just a quiet annoyance you’ve grudgingly learned to put up with, or a life defining issue that makes it hard to move forward. Whatever it is, Alex Goldman — reporter, radio producer, and overconfident idiot — will get to the bottom of it (if there’s a bottom to be found. Results may vary). Follow Alex as he figures out not only the vast hidden mechanisms that create these problems, but works with you, the listener, to find a solution. Or at least enough of an explanation that you’re ok with the annoyance. He’s not perfect. Hyperfixed is a proud member of Radiotopia from PRX, a network of independent and listener-supported podcasts. Discover audio with vision at radiotopia.fm.  Submit your problems and sign up for bonus episodes and much more at hyperfixedpod.com

  1. The Cat Drug Black Market

    1 DAY AGO

    The Cat Drug Black Market

    When Marlena's cat was diagnosed with a terminal disease, she found herself seeking help not from a vet, but a series of websites and Facebook groups. The first in a three-part series. Support independent journalism by becoming a part of our premium user community. Join the discord, get access to exclusive merch (soon), and much much more.  https://www.hyperfixedpod.com/join LINKS: GS treatment available in pharmacies: https://bestfriends.org/sites/default/files/2024-11/Network_09%20Webinar_FIP%20Treatment_US-Pharmacy-FIP-Treatment-Options.pdf Dr. Pedersen's 2019 paper FIP Warriors Facebook Group Gilead's statement:  Since Gilead identified GS-441524 as a potential treatment for cats with feline infectious peritonitis (FIP), we made it available to institutions with the expertise to advance medicines for veterinary use. This is why we shared GS-441524 with UC Davis to research its impact on FIP. GS-441524 is an intermediate in the synthesis of remdesivir, an approved treatment for COVID-19. Gilead’s supply of GS-441524 was and continues to be used to manufacture remdesivir to meet the demands of COVID-19. Today, remdesivir has been made available to more than 14.5 million patients around the world, including more than 8.1 million in low- and lower-middle income countries. In parallel, Gilead has made progress in studies identifying prodrugs of GS-441524 with improved oral bioavailability that could be further investigated as a therapeutic for FIP in cats. Discussions with suitable veterinary specialty companies are ongoing, but to-date we have not identified an appropriate partner. Gilead supports finding a solution for FIP at the earliest opportunity. Learn about your ad choices: dovetail.prx.org/ad-choices
    43 min
  2. You Might Also Like: Clinical Trialblazers

    1 DAY AGO · BONUS

    You Might Also Like: Clinical Trialblazers

    Introducing The Finnish Formula: Finding Balance and Building Innovation with Dr. Antti Vuolanto from Clinical Trialblazers. Follow the show: Clinical Trialblazers In this episode of Clinical Trialblazers, Dr. Antti Vuolanto, CEO of Herantis Pharma Plc, shares his unconventional journey into the biotech industry, from bioengineering to leading a company focused on central nervous system (CNS) diseases. He discusses the scientific innovation behind HER096, a potential game-changer for Parkinson's disease, and the challenges of drug development. Beyond the science, Dr. Vuolanto offers profound lessons on the importance of building trust with colleagues and investors, the importance of taking risks, and the importance of work-life balance (a Finnish secret to happiness!). This episode highlights the power of mentorship, honest communication, and a deep commitment to impacting patients’ lives. He discusses the importance of mentorship, the challenges of drug development, and the significance of building trust with investors.  We hope you enjoyed this week’s episode of Clinical Trialblazers. Please take a moment to rate and review this podcast wherever you listen. Special thanks to our production partner, Wonder Media Network. Our producer is Brittany Martinez, our editor is Gianna Palmer and our production assistant is Joia Putnoi. DISCLAIMER: Please note, this is an independent podcast episode not affiliated with, endorsed by, or produced in conjunction with the host podcast feed or any of its media entities. The views and opinions expressed in this episode are solely those of the creators and guests. For any concerns, please reach out to [email protected].

About

Maybe it’s just a quiet annoyance you’ve grudgingly learned to put up with, or a life defining issue that makes it hard to move forward. Whatever it is, Alex Goldman — reporter, radio producer, and overconfident idiot — will get to the bottom of it (if there’s a bottom to be found. Results may vary). Follow Alex as he figures out not only the vast hidden mechanisms that create these problems, but works with you, the listener, to find a solution. Or at least enough of an explanation that you’re ok with the annoyance. He’s not perfect. Hyperfixed is a proud member of Radiotopia from PRX, a network of independent and listener-supported podcasts. Discover audio with vision at radiotopia.fm.  Submit your problems and sign up for bonus episodes and much more at hyperfixedpod.com

You Might Also Like

To listen to explicit episodes, sign in.

Stay up to date with this show

Sign in or sign up to follow shows, save episodes and get the latest updates.

Select a country or region

Africa, Middle East, and India

Asia Pacific

Europe

Latin America and the Caribbean

The United States and Canada